LadRx (OTCMKTS:CYTR – Get Rating) and Inhibrx (NASDAQ:INBX – Get Rating) are both small medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, dividends, analyst ratings, and institutional ownership.
This is a summary of the current recommendations and price targets for LadRx and Inhibrx as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LadRx 0 0 0 0 N/A Inhibrx 0 0 4 0 3.00
Inhibrx has a consensus price target of $45.25, indicating a potential upside potential of 98.38%. Given Inhibrx’s higher potential upside potential, analysts clearly believe that Inhibrx is cheaper than LadRx.
Volatility & Risk
LadRx has a beta of 1.96, indicating its stock price is 96% more volatile than the S&P 500. In comparison, Inhibrx has a beta of 2.96, indicating its stock price is 196% more volatile than that S&P 500. Insider and Institutional Ownership
0.1% of LadRx shares are held by institutional investors. In comparison, 72.8% of Inhibrx shares are held by institutional investors. 12.8% of LadRx shares are held by company insiders. In comparison, 25.8% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers, and endowments believe a stock is poised for long-term growth.
This table compares the net margins, return on equity, and return on assets of LadRx and Inhibrx.
Net Margin Return on Equity Return on Assets LadRx N/A -67.61% -45.39% Inhibrx -6,625.27% -1,278.54% -71.71% Valuation & Return
This table compares the revenue, earnings per share (EPS) and valuation of LadRx and Inhibrx.
Gross Sales Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LadRx N/A zn
LadRx has higher earnings but lower earnings than Inhibrx. Inhibrx is trading at a lower price-to-earnings multiple than LadRx, suggesting it’s the cheaper of the two stocks at the moment.
LadRx Corporation, a biopharmaceutical company, is engaged in the discovery and development of therapeutics to treat patients with cancer. The company’s advanced drug conjugate, in late-stage clinical trials, aldoxorubicin, is a version of the cancer drug doxorubicin. Its preclinical therapeutics include linker-activated drug releases 7, 8, 9, and 10, which target cancer. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a pipeline of novel biological therapeutic candidates. The Company’s therapeutic candidates include INBRX-109, a tetravalent death receptor 5 agonist in Phase 2 clinical trials for the treatment of cancers such as chondrosarcoma, mesothelioma and pancreatic adenocarcinoma; INBRX-105, a tetravalent programmed death ligand 1 conditional agonist and a 4-1BB conditional agonist in Phase 1 clinical trials for the treatment of patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1-antitrypsin (AAT)-Fc fusion protein therapeutic candidate that is in Phase 1 clinical trials for use in treating patients with AAT deficiency. It also offers INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Receive News & Ratings for LadRx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LadRx and related companies with MarketBeat.com’s FREE daily email newsletter.